

## PRESS RELEASE

## EOS imaging Announces Exclusive Partnership and Licensing Agreement for Virtual Patient Models

*Agreement with Anatoscope will bring virtual patient avatars based on 2D/3D EOS image data to the advanced software applications, EOSapps*

**Paris, July 21, 2016** - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today an exclusive partnership with Anatoscope (Montpellier, France) to combine Anatoscope's virtual patient models with EOS 2D/3D images and datasets into the EOS apps for advanced orthopaedic applications. The first applications will be available in 2017.

Anatoscope, a start-up company created in 2015, develops software solutions to generate 3D digital avatars that are based on a patient's medical images which allow the simulation of medical treatments. The team has robust experience in developing patient models from CT scans and MR images.

The exclusive agreement and associated licensing rights cover the development of patient avatars from EOS 2D/3D images and datasets as well as their deformation. Initially, the model will take into account the patient corpulence and external body shape in combination with the patient's skeletal images from their EOS exam. The first applications for this technology will be introduced into the EOS platform in 2017.

Marie Meynadier, CEO of EOS imaging, said, *"Introducing a virtual patient model into our advanced 3D orthopedic applications will assist surgeons as they plan their patient's spine treatments. The Anatoscope agreement complements the ongoing internal developments with our partner Spinologics to bring within our EOSapps the most cost-effective and relevant solutions to image-based planning, simulation and control of orthopedic therapies."*

For more information, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**

EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI



### About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.



## PRESS RELEASE

### **Contacts:**

#### **Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

#### **NewCap**

Financial communication and investor relations

Valentine Brouchet

Ph: +33 (0)1 44 71 94 96

[eosimaging@newcap.eu](mailto:eosimaging@newcap.eu)

#### **The Ruth Group (US)**

Press relations / Joanna Zimmerman

Ph: 646-536-7006

[jjzimmerman@theruthgroup.com](mailto:jjzimmerman@theruthgroup.com)